These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37030573)

  • 1. Real-life experience with IV fosfomycin in Canada: Results from the Canadian LEadership on Antimicrobial Real-life usage (CLEAR) registry.
    Zhanel G; Baxter M; Wong M; Mirzanejad Y; Lee A; Dhami R; Kosar J; Werry D; Irfan N; Tessier JF; Girourd G; Tascini C; von den Baumen TR; Walkty A; Karlowsky JA
    J Glob Antimicrob Resist; 2023 Jun; 33():171-176. PubMed ID: 37030573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
    Zhanel GG; Dhami R; Baxter M; Kosar J; Cervera C; Irfan N; Zvonar R; Borgia S; Tessier JF; Dow G; Ariano R; Dube M; Savoie M; Bassetti M; Walkty A; Karlowsky JA
    J Glob Antimicrob Resist; 2021 Jun; 25():346-350. PubMed ID: 33984530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
    Zhanel G; Silverman M; Malhotra J; Baxter M; Rahimi R; Irfan N; Girouard G; Dhami R; Kucey M; Stankus V; Schmidt K; Poulin S; Connors W; Tascini C; Walkty A; Karlowsky J
    J Glob Antimicrob Resist; 2024 Jun; 38():154-157. PubMed ID: 38908823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry.
    Zhanel GG; Kosar J; Baxter M; Dhami R; Borgia S; Irfan N; MacDonald KS; Dow G; Lagacé-Wiens P; Dube M; Bergevin M; Tascini C; Keynan Y; Walkty A; Karlowsky J
    J Glob Antimicrob Resist; 2021 Mar; 24():335-339. PubMed ID: 33540083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial.
    del Río A; Gasch O; Moreno A; Peña C; Cuquet J; Soy D; Mestres CA; Suárez C; Pare JC; Tubau F; Garcia de la Mària C; Marco F; Carratalà J; Gatell JM; Gudiol F; Miró JM;
    Clin Infect Dis; 2014 Oct; 59(8):1105-12. PubMed ID: 25048851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
    Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
    Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
    Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current clinical use of intravenous fosfomycin in ICU patients in two European countries.
    Putensen C; Ellger B; Sakka SG; Weyland A; Schmidt K; Zoller M; Weiler N; Kindgen-Milles D; Jaschinski U; Weile J; Lindau S; Kieninger M; Faltlhauser A; Jung N; Teschendorf P; Adamzik M; Gründling M; Wahlers T; Gerlach H; Litty FA
    Infection; 2019 Oct; 47(5):827-836. PubMed ID: 31190298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies.
    Falagas ME; Roussos N; Gkegkes ID; Rafailidis PI; Karageorgopoulos DE
    Expert Opin Investig Drugs; 2009 Jul; 18(7):921-44. PubMed ID: 19548851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fosfomycin in the pediatric setting: Evidence and potential indications.
    Baquero-Artigao F; Del Rosal Rabes T
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):55-61. PubMed ID: 31131593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections.
    Zhanel GG; Zhanel MA; Karlowsky JA
    Can J Infect Dis Med Microbiol; 2020; 2020():8513405. PubMed ID: 32300381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial.
    Shaw E; Miró JM; Puig-Asensio M; Pigrau C; Barcenilla F; Murillas J; Garcia-Pardo G; Espejo E; Padilla B; Garcia-Reyne A; Pasquau J; Rodriguez-Baño J; López-Contreras J; Montero M; de la Calle C; Pintado V; Calbo E; Gasch O; Montejo M; Salavert M; Garcia-Pais MJ; Carratalà J; Pujol M; ; ;
    BMJ Open; 2015 Mar; 5(3):e006723. PubMed ID: 25762232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat Gram-negative bacterial infections.
    Abdallah TAK; Elajez R; Ibrahim TB; Alimam AB; Omrani AS
    J Infect Public Health; 2021 Nov; 14(11):1620-1622. PubMed ID: 34628083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
    Stock I
    Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
    Reffert JL; Smith WJ
    Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fosfomycin: use beyond urinary tract and gastrointestinal infections.
    Falagas ME; Giannopoulou KP; Kokolakis GN; Rafailidis PI
    Clin Infect Dis; 2008 Apr; 46(7):1069-77. PubMed ID: 18444827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.
    Neuner EA; Sekeres J; Hall GS; van Duin D
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5744-8. PubMed ID: 22926565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test.
    Croughs PD; Konijnendijk-de Regt M; Yusuf E
    Microbiol Spectr; 2022 Apr; 10(2):e0250421. PubMed ID: 35352940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.